{"entity":{"id":"complete-response","kind":"term","name":"Complete response","aka":["complete responses","CR","complete responder","complete responders","radiographic complete response","clinical complete response","cCR"],"tldr":"All detectable signs of the tumour have vanished on scans and examination after treatment. The best result a trial can record for an individual patient, though microscopic disease may remain.","summary":"Under RECIST, complete response means every target lesion has disappeared and any lymph nodes have shrunk below 10 mm; it must be confirmed on a repeat scan. Complete responses are common in lymphomas and germ-cell tumours and were historically rare in solid tumours, so their appearance with immunotherapy and cell therapy (around 20% in metastatic melanoma with ipilimumab plus nivolumab, most of them lasting) was a genuine change. Pathologic complete response is the surgical equivalent: no cancer cells found in the removed tissue after pre-operative treatment.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors"}],"tags":[],"related":["partial-response","stable-disease","progression","orr","recist","pcr","remission","duration-of-response"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinic basics"},"route":"/terms/complete-response/","neighbours":{"term":[{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/"},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/"},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/"},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"paper":[{"id":"paper-transcend-nhl-001-liso-cel-lancet-2020","kind":"paper","name":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","route":"/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/"},{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/"},{"id":"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004","kind":"paper","name":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","route":"/key-papers/paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004/"},{"id":"paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011","kind":"paper","name":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","route":"/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/"},{"id":"paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023","kind":"paper","name":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023/"},{"id":"paper-elm-2-odronextamab-follicular-ann-oncol-2024","kind":"paper","name":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/"},{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/"},{"id":"paper-elara-tisagenlecleucel-follicular-nat-med-2022","kind":"paper","name":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","route":"/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/"},{"id":"paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","kind":"paper","name":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","route":"/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/"}],"trial":[{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/"},{"id":"fortplus","kind":"trial","name":"FORTplus","route":"/trials/fortplus/"},{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"rosewood","kind":"trial","name":"ROSEWOOD","route":"/trials/rosewood/"},{"id":"smile-enktl","kind":"trial","name":"SMILE","route":"/trials/smile-enktl/"},{"id":"transcend-nhl-001","kind":"trial","name":"TRANSCEND NHL 001","route":"/trials/transcend-nhl-001/"}],"person":[{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","route":"/people/angelita-habr-gama/"}]}}